Propanc Biopharma shares surge 31.99% intraday after filing provisional patents for resistant cancer and fibrosis treatments.
ByAinvest
Monday, Dec 1, 2025 12:41 pm ET1min read
PPCB--
Propanc Biopharma surged 31.99% intraday after announcing the submission of two provisional patents for novel treatments targeting resistant cancer and fibrosis, filed via its Australian subsidiary. The patents, developed through joint research with Spanish universities, mark the first expansion of its lead product, PRP, into fibrosis, a high-unmet-need chronic condition. CEO James Nathanielsz highlighted the patents as a “significant turning point,” with a planned 2026 Phase 1b First-In-Human study to define PRP’s therapeutic dose. The news underscores Propanc’s potential to commercialize PRP across multiple disease areas, positioning it as a non-cytotoxic therapy addressing both oncology and fibrotic disorders. The filing also signals global IP strategy, with plans to pursue patents in key jurisdictions, enhancing long-term commercial prospects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet